Exploring the Cortical Hemodynamic Response of Excitatory Brain Stimulation: a Pilot Study
September 14, 2022 updated by: Dr Georg Kranz, The Hong Kong Polytechnic University
Intermittent theta-burst stimulation (iTBS) is a promising treatment for major depressive disorder. However, fewer than 50% of patients show sufficient response. Therefore, the optimal treatment protocol is worth investigating. Recent studies show that the relationship between stimulation intensity and prefrontal hemodynamic response is not linear but in an inverse U-shape by exploring the hemodynamic changes before and after iTBS. Concurrent transcranial magnetic stimulation (TMS)/functional near-infrared spectroscopy (fNIRS) setup allows the investigators to observe the prefrontal hemodynamic response during stimulation.
The aim of this study is to investigate the effects of different intensities on brain activity during and after the stimulation using fNIRS.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Please refer to the full proposal
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hong Kong, Hong Kong
- The Hong Kong Polytechnic University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Right-handed
Exclusion Criteria:
- history of epilepsy, seizures, or convulsions
- current or past diagnosis of neurological disorders, such as head injuries, strokes, encephalitis, epilepsy, Parkinson's, or Alzheimer's
- current or past diagnosis of psychiatric disorders, such as depression, anxiety, schizophrenia, or autism
- with metal implants, such as a cochlear implant, neurostimulator, or cardiac pacemaker
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Prefrontal hemodynamic response to 50% rMT iTBS
Participants will receive 50% rMT iTBS over left DLPFC in this arm.
The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
|
The iTBS will be applied over lDLPFC with three different intensities.
The investigators put the NIRS probe under the TMS coil to detect the hemodynamic signal simultaneously, and the applied rMT was adjusted based on Stokes et al., 2007.
The equation is AdjMT% = MT + 2.8 * (Dsitex - Dm1), and the thickness of the probe is 6mm, therefore, 2.8*6=16.8(%)
were added to the normal intensity.
Other Names:
|
|
Experimental: Prefrontal hemodynamic response to 70% rMT iTBS
Participants will receive 70% rMT iTBS over left DLPFC in this arm.
The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
|
The iTBS will be applied over lDLPFC with three different intensities.
The investigators put the NIRS probe under the TMS coil to detect the hemodynamic signal simultaneously, and the applied rMT was adjusted based on Stokes et al., 2007.
The equation is AdjMT% = MT + 2.8 * (Dsitex - Dm1), and the thickness of the probe is 6mm, therefore, 2.8*6=16.8(%)
were added to the normal intensity.
Other Names:
|
|
Experimental: Prefrontal hemodynamic response to 90% rMT iTBS
Participants will receive 90% rMT iTBS over left DLPFC in this arm.
The prefrontal hemodynamic response will be observed simultaneously before, during, and after iTBS using fNIRS.
|
The iTBS will be applied over lDLPFC with three different intensities.
The investigators put the NIRS probe under the TMS coil to detect the hemodynamic signal simultaneously, and the applied rMT was adjusted based on Stokes et al., 2007.
The equation is AdjMT% = MT + 2.8 * (Dsitex - Dm1), and the thickness of the probe is 6mm, therefore, 2.8*6=16.8(%)
were added to the normal intensity.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Oxygenated hemoglobin (HbO) change compared to baseline
Time Frame: During and post TBS-fNIRS measurement, up to 3 months
|
iTBS-induced HbO change in the DLPFC before, during and after stimulation
|
During and post TBS-fNIRS measurement, up to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Deoxygenated hemoglobin (HbR) Change compared to baseline
Time Frame: During and post TBS-fNIRS measurement, up to 3 months
|
iTBS-induced HbR change in the DLPFC before, during and after stimulation
|
During and post TBS-fNIRS measurement, up to 3 months
|
|
Oxygen saturation change compared to baseline
Time Frame: During and post TBS-fNIRS measurement, up to 3 months
|
iTBS-induced oxygen saturation change in the DLPFC before, during and after stimulation
|
During and post TBS-fNIRS measurement, up to 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Georg S Kranz, PhD, The Hong Kong Polytechnic University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 1, 2022
Primary Completion (Actual)
August 31, 2022
Study Completion (Actual)
August 31, 2022
Study Registration Dates
First Submitted
June 16, 2022
First Submitted That Met QC Criteria
June 16, 2022
First Posted (Actual)
June 22, 2022
Study Record Updates
Last Update Posted (Actual)
September 15, 2022
Last Update Submitted That Met QC Criteria
September 14, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- HSEARS20200120005-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.